Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade for Refractory Autoimmune Cytopenia Post-SCT
NCT01929980Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jul 2012
- Primary completion
- May 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in autoimmune cytopenia, sponsored by Cincinnati Children's Hospital Medical Center. Started Jul 2012; status: completed.
02
Drugs
bortezomib
03
Conditions
autoimmune cytopenia
Beyond the preview
Go deeper on NCT01929980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01929980.